news_6

Celltrion Healthcare Presents Positive One-Year Data for the First High-Concentration, Low-Volume and Citrate-Free Biosimilar Adalimumab, YuflymaTM (CT-P17) in Patients With Rheumatoid Arthritis at EULAR 2021

One-year data have shown equivalent efficacy and comparable safety for Yuflyma™ (CT-P17) against reference adalimumab in patients with moderate-to-severe active...

news_6

HighTide Announces First Patient Dosed in Phase 2 PRONTO-PBC Clinical Study Evaluating HTD1801 in Adult Patients with Primary Biliary Cholangitis

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for...